Literature DB >> 22759563

A modified Essen stroke risk score for predicting recurrent cardiovascular events: development and validation.

Shigeki Sumi1, Hideki Origasa, Kiyohiro Houkin, Yasuo Terayama, Shinichiro Uchiyama, Hiroyuki Daida, Hiroshi Shigematsu, Shinya Goto, Kortaro Tanaka, Susumu Miyamoto, Kazuo Minematsu, Masayasu Matsumoto, Yasushi Okada, Motoki Sato, Norihiro Suzuki.   

Abstract

BACKGROUND: The Essen stroke risk score is widely applied to predict the risk of recurrent ischemic stroke. We developed a modified Essen stroke risk score and validated it using a large prospective Effective Vascular Event REduction after STroke (EVEREST) registry including 3588 patients with ischemic stroke in Japan. Patients with cardioembolic stroke were excluded, and follow-up was one-year.
METHODS: The modified Essen stroke risk score was calculated from scores for waist circumference, stroke subtype by etiology, and gender in addition to age, hypertension, diabetes mellitus, previous myocardial infarction, other cardiovascular diseases except myocardial infarction and atrial fibrillation, peripheral artery disease, smoking, and previous stroke or transient ischemic attack. A multiple logistic regression model identified the predictors (each assigned one or two points) and provided c-statistics for the modified Essen stroke risk score. We considered two outcomes, recurrent ischemic stroke and cardiovascular events (defined as the combined outcomes of fatal or nonfatal stroke, myocardial infarction, nonfatal unstable angina, and cardiac death).
RESULTS: Recurrent ischemic stroke occurred in 121 patients (3·7%) and cardiovascular events occurred in 133 (4·0%) within a year. The c-statistic (used for discrimination) was 0·632 for recurrent stroke and 0·640 for cardiovascular events. Patients scoring 6 or greater were classified as high risk, otherwise were classified as low risk. Kaplan-Meier analysis revealed that the modified risk score was more predictive than the Essen stroke risk score in both men and women.
CONCLUSIONS: The modified Essen stroke risk score increased the ability of the Essen stroke risk score to predict recurrent cardiovascular events. Patients with a high modified Essen stroke risk score should be candidates for intensified secondary prevention strategies.
© 2012 The Authors. International Journal of Stroke © 2012 World Stroke Organization.

Entities:  

Mesh:

Year:  2012        PMID: 22759563     DOI: 10.1111/j.1747-4949.2012.00841.x

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  5 in total

1.  Relevance of stroke subtype in vascular risk prediction.

Authors:  Angel Ois; Elisa Cuadrado-Godia; Ana Rodríguez-Campello; Eva Giralt-Steinhauer; Jordi Jiménez-Conde; Miguel Lopez-Cuiña; Miguel Ley; Carol Soriano; Jaume Roquer
Journal:  Neurology       Date:  2013-07-03       Impact factor: 9.910

2.  Essen score in the prediction of cerebrovascular events compared with cardiovascular events after ischaemic stroke or transient ischaemic attack: a nationwide registry analysis.

Authors:  Long Li; Ze-Ning Jin; Yue-Song Pan; Jing Jing; Xia Meng; Yong Jiang; Hao Li; Cai-Xia Guo; Yong-Jun Wang
Journal:  J Geriatr Cardiol       Date:  2022-04-28       Impact factor: 3.327

3.  Prediction Model Construction for Ischemic Stroke Recurrence with BP Network and Multivariate Logistic Regression and Effect of Individualized Health Education.

Authors:  Ting Lu; Yun Wang
Journal:  Comput Math Methods Med       Date:  2022-06-22       Impact factor: 2.809

Review 4.  Formal and informal prediction of recurrent stroke and myocardial infarction after stroke: a systematic review and evaluation of clinical prediction models in a new cohort.

Authors:  Douglas D Thompson; Gordon D Murray; Martin Dennis; Cathie L M Sudlow; William N Whiteley
Journal:  BMC Med       Date:  2014-04-04       Impact factor: 8.775

Review 5.  Clinical Risk Score for Predicting Recurrence Following a Cerebral Ischemic Event.

Authors:  Durgesh Chaudhary; Vida Abedi; Jiang Li; Clemens M Schirmer; Christoph J Griessenauer; Ramin Zand
Journal:  Front Neurol       Date:  2019-11-12       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.